ChemicalBook >> CAS DataBase List >>Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1)

Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1)

CAS No.
1629063-79-1
Chemical Name:
Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1)
Synonyms
Ibiglustat hydrochloride;Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1)
CBNumber:
CB710777760
Molecular Formula:
C20H25ClFN3O2S
Molecular Weight:
425.95
MDL Number:
MOL File:
1629063-79-1.mol
MSDS File:
SDS
Last updated:2026-05-11 19:39:08

Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) Properties

FDA UNII OK1S17555O

Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) Chemical Properties, Uses, Production

Uses

Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].

References

[1] Viel C, et al. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021;11(1):20945. Published 2021 Oct 22. DOI:10.1038/s41598-021-00404-5
[2] Peterschmitt MJ, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021;10(1):86-98. DOI:10.1002/cpdd.865
[3] Stojkovska I, et al. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease. Cell Tissue Res. 2018;373(1):51-60. doi:10.1007/s00441-017-2704-y DOI:10.1007/s00441-017-2704-y
[4] Itier JM, et al. Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease. J Inherit Metab Dis. 2014 Nov;37(6):1013-22. DOI:10.1007/s10545-014-9724-5

Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) Preparation Products And Raw materials

Raw materials

Preparation Products

Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) Suppliers

Global Suppliers ( 2)
Supplier Tel Email Country ProdList Advantage
TargetMol Chemicals Inc. 15002134094 marketing@targetmol.cn China 29874 58
TargetMol Chemicals Inc. 13564774135 marketing@targetmol.com United States 19950 58

View Latest Price from Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Ibiglustat hydrochloride pictures 2026-05-11 Ibiglustat hydrochloride
1629063-79-1
$1670.00-2800.00 10g TargetMol Chemicals Inc.
Carbamic acid, N-[1-[2-(4-fluorophenyl)-4-thiazolyl]-1-methylethyl]-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) Ibiglustat hydrochloride 1629063-79-1 C20H25ClFN3O2S